In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

Illumina, Inc.'s acquisition of GRAIL, Inc. was disastrous and created all kinds of problems, but the company is refocusing on its profitable core gene sequencing business. ILMN's revenue growth ...

While Illumina completed the takeover of Grail last September, it has maintained the business as a separate subsidiary company while it waits for the outcome of antitrust reviews in the US and Europe.

Nearly four years after pitching for Grail, Illumina finally separated the cancer blood test developer. To expand its reach in single-cell analysis and multiomics research, Illumina acquired ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company ... Index will become effective before the market opens on December 23. Illumina, Inc. (NASDAQ:ILMN) was removed from the index.

We recently compiled a list of the 15 Stocks Targeted By Activist Hedge Funds. In this article, we are going to take a look ...

Grail was officially spun off from Illumina in June 2024 as the European Commission prohibited Illumina's acquisition of Grail in 2022. Grail's sole product is the Galleri Test, which is a multi ...

According to the decision of the EU's Court of Justice in Luxembourg, the European Commission had no right to block the acquisition of Grail Inc. by Illumina Inc. for $7 billion. This is stated in the ...

Also Read: European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine Nearly four years after pitching for Grail, Illumina finally separated the ...